Results 151 to 160 of about 50,110 (265)

Case Report: Probable CLIPPERS in a patient with cutaneous T-cell lymphoma in remission: 5-year follow-up. [PDF]

Front Immunol
Hong K, Liang L, Li R, Song Z, Zhang M, Bu H, Zhang Y.   +6 more
europepmc   +1 more source

High Level of Component C1q Binding Protein (C1QBP) is Associated With Poor Prognosis and Dysfunction of Mast Cells in Lung Adenocarcinoma

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Component C1q binding protein (C1QBP) is known as an important regulator of mitochondrial plasticity and is involved in antitumor immune response in cancers. Nevertheless, its role in lung adenocarcinoma (LUAD) still remains largely unknown.
Wei Li, Guangnan Huang, Lizhong Zeng, Wenhui Dang, Ting Jiao, Yonghong Zhang, Mengying Zhang, Shuru Zhou, Liping Chen, Shuanying Yang   +9 more
wiley   +1 more source

Assessing content validity of the functional assessment of cancer therapy-cutaneous T-cell lymphoma (FACT-CTCL): a qualitative study. [PDF]

J Patient Rep Outcomes
Raymundo C, Park JJS, Di M, Larocca C, Cella D, Shinohara MM.   +5 more
europepmc   +1 more source

Empirical PK/PD Model for Differentiating Intrinsic Dosing Rules by Therapeutic Indication With Relevance for HIV‐1 Latency Reversal

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1414-1426, November 2026.
Romidepsin (RMD), an FDA‐approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency‐reversing activity in vitro but has yielded suboptimal outcomes in kick‐and‐kill HIV‐cure trials when administered as a 5 mg/m2 infusion.
Lauren A. R. Tompkins, Amanda Poliseno, Airlie Ward, Edward P. Browne, Cassandra Gilbert, Craig Sykes, Angela D. M. Kashuba, Mackenzie L. Cottrell   +7 more
wiley   +1 more source

Immunomodulation in Cutaneous T Cell Lymphoma

Frontiers in Oncology, 2019
Martina Ferranti, Giulia Tadiotto Cicogna, Irene Russo, Mauro Alaibac   +3 more
doaj   +1 more source

Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are the most aggressive forms of cutaneous T‐cell lymphoma and remain associated with a poor prognosis and heterogeneous therapeutic approaches. Recent advances, including targeted therapies and improved transplant strategies, have substantially expanded treatment options, highlighting ...
Francesco Onida, Pietro Quaglino, Julia Scarisbrick, Anna Sureda, Emmilia Hodak, Evangelia Papadavid, Silvia Alberti‐Violetti, Martine Bagot, Lorenzo Cerroni, Amrita Goyal‐O'Leary, Rudolf Stadler, Rein Willemze, Jasmine Zain, Marco Ardigò, Emilio Berti, Adèle de Masson, Rafael F. Duarte, Francine Foss, Eva González‐Barca, Joan Guitart, Pablo Ortiz‐Romero, Alessandro Pileri, Pierluigi Porcu, Henry M. Prince, Sima Rozati, Serena Rupoli, Maarten H. Vermeer, Sean Whittaker, Nicola Pimpinelli, Pier Luigi Zinzani   +29 more
wiley   +1 more source

Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study. [PDF]

Blood Neoplasia
Sacknovitz Y, Erem AS, Kent JA, Albitar M, Feldman T, Pro B, Tolu SS, Gru AA, Geskin L.   +8 more
europepmc   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Inflammatory and Infectious Cutaneous Entities Resembling Cutaneous T-Cell Lymphoma (CTCL): An Integrated Clinicopathological Review. [PDF]

Dermatopathology (Basel)
Nasser Eldin J, El Tayar E, Abbas O, Bhawan J.   +3 more
europepmc   +1 more source

MEF2A Promotes Keratinocyte Proliferation and Migration Under High‐Glucose Conditions via Activation of the PI3K/AKT Signaling Pathway: Implications for Diabetic Wound Healing

The Journal of Gene Medicine, Volume 28, Issue 11, November 2026.
MEF2A promotes keratinocyte function in diabetic wound healing by activating the PI3K/AKT signaling pathway. In vivo studies revealed an upregulation of MEF2A expression in the skin wound tissues of diabetic mouse models. In vitro functional experiments confirmed that under high‐glucose conditions, MEF2A overexpression activates the PI3K/AKT signaling ...
Yuan Xue, Min Xuan, Linlin Feng, Jingwen Kuang, Bin Xu, Limin Wei, Pengcheng Xu   +6 more
wiley   +1 more source